Breast Cancer Therapeutics in Southeast Asia Market Is Projected Around USD 2.7 Billion By 2022: Radiant Insights,Inc
Summary
Breast cancer is a malignant
neoplasm that begins in the breast tissue. Most breast cancers are invasive
cancers that have grown beyond the ducts or lobules and can metastasize to
other parts of the body through the bloodstream and the lymphatic system.
Broadly, patients can be segmented into two types: the human epidermal growth
factor receptor (HER) 2-negative segment and the HER2-positive segment.
HER2-positive breast cancer is aggressive and, historically, has had a worse
overall survival than HER2-negative disease, which is considered less
aggressive.
In HER2-negative breast cancer, a
number of different factors can influence the choice of therapy that a patient
receives, including the stage of the cancer, the hormonal receptor status of
the cancer (ER-positive or -negative and PR-positive or -negative) and whether
the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is
a setting with incredibly high unmet needs, with no targeted therapy options
being available. Chemotherapy is the mainstay of treatment in this setting. For
HR-positive disease, endocrine therapies are the primary treatment.
View Full Report with TOC @ http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022
Survival for HER2-positive breast
cancer patients has increased, due to established disease management strategies
using numerous combinations of chemotherapy along with targeted therapies such
as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer
therapies are expected to significantly improve survival outcomes in all lines
of the disease. The introduction of Herceptin, the first HER2-targeting agent
for metastatic disease, greatly improved the outcome of patients with
HER2-positive breast cancer, bringing survival rates close to those of
HER2-negative, HR-positive breast cancer.
In most Southeast Asian
countries, the highest unmet need lies in the lack of a defined treatment plan
for the disease, poor affordability, and patients continuing to rely on the use
of chemotherapies in the later lines of treatment. It is important for drug
companies to consider the evolving reimbursement landscape when determining
pricing strategies across the Southeast Asian markets, because this will
significantly impact the uptake of premium drugs.
Request A Sample Copy of This Report at: http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022/request-sample
Scope
The current Southeast Asia breast
cancer market contains well-established novel targeted products such as Perjeta
and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such
as Ibrance.
·
Which
drugs are used as the standard treatment in each setting of the disease?
·
What are
the competitive advantages of the existing novel drugs?
·
Do branded
therapies show continued growth, and how does their expected uptake influence
the market growth over the forecast period?
·
There are
about 1,150 active pipeline molecules. The pipeline contains a range of
molecule types and molecular targets, including those that are well established
in breast cancer, and novel, first-in-class therapies.
·
Which
molecular targets appear most frequently in the pipeline?
·
There is
currently no approved therapy in the TNBC setting. Are there any drugs in the
pipeline to improve treatment for TNBC?
·
Targets
that are not currently represented by marketed products are virtually absent
from the late-stage pipeline. Does the early stage pipeline have experimental
molecules designed to target novel pathways?
Analysis of clinical trials since
2006 identified that the failure rates of breast cancer molecules were highest
in Phase II, at 59%, with the overall attrition rate for breast cancer standing
at 85%.
·
How do
failure rates vary by stage of development, molecule type, and molecular
target?
·
How do
other factors, such as average trial duration and trial size, influence the
costs and risks associated with product development?
·
The
breast cancer Southeast Asian market will be valued at $2.7 billion in 2022,
growing from $942.3m in 2015 at a CAGR of 16.2%.
·
Despite
an array of treatments being available for breast cancer, there is still an
unmet need in the Southeast Asian markets related to low uptake of targeted
therapies. Will this scenario change during the forecast period?
·
Market
forecasts indicate that South Korea will continue to be the largest market in
Southeast Asia, due to the emergence of novel therapies and the continued
uptake of branded therapies.
·
How will
the annual cost of therapy and market size vary between the eight Southeast
Asian markets?
·
What are
the factors that contribute to the increase in ACoT and market size for each of
the assessed countries?
·
How will
branded therapies be affected by upcoming pipeline therapies in each of the
assessed countries?
·
How will
the potential launch of biosimilars influence each country?
·
Will the
launch of biosimilars or emerging pipeline molecules threaten the commercial
success of existing drugs?
·
Various
drivers and barriers will influence the market over the forecast period.
·
What
barriers limit the uptake of premium-priced therapeutics in the assessed
countries?
·
What
factors are most likely to drive the market in these countries?
Reasons to buy
This report will allow you to -
·
Understand
the current clinical and commercial landscape by considering disease
pathogenesis, diagnosis, prognosis, and the treatment options available at each
stage of diagnosis, including a clinical comparison of marketed therapies.
·
Visualize
the composition of the breast cancer market in terms of dominant therapies,
with their clinical and commercial standing. Unmet needs are also highlighted
to allow a competitive understanding of gaps in the market.
·
Analyze
the breast cancer pipeline and stratify pipeline therapies by stage of
development, molecule type and molecular target.
·
Understand
the potential of late-stage therapies, with extensive profiles of products that
could enter the market over the forecast period, highlighting clinical
performance, potential commercial positioning, and how they will compete with
other therapies.
·
Predict
breast cancer market growth in the eight Southeast Asian markets, with epidemiological
and annual cost of therapy forecasts, as well as analysis of the contributions
of promising late-stage molecules to market growth.
·
Identify
commercial opportunities in the breast cancer deals landscape by analyzing
trends in licensing and co-development deals.
Browse Other Reports of This Category at: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to
meet their market research and business intelligence requirements. We assist
and facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
Media Contact:
Company Name: Radiant
Insights, Inc
Contact Person: Michelle
Thoras
Email:
sales@radiantinsights.com
Phone: (415) 349-0054
Address: 28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Comments
Post a Comment